Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs WD 40 Company (WDFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs WD 40 Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while WD 40 Company trades at $267.3 (market cap $3.56B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.2× WD 40 Company's market cap, and WD 40 Company pays a 1.54% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WDFC | |
|---|---|---|
Market Cap | $39.89B | $3.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $264.91 |
52-Week Low | $278.09 | $187.52 |
Enterprise Value | $38.15B | $3.61B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
WDFC stock trades at $264.91, up 10.65% ($25.49) on strong Q2 2026 earnings that beat estimates with EPS of $2.33 versus $1.58 expected. The technical outlook is bullish with support at $237 and resistance at $245. Fundamentals show robust revenue growth to $675M in 2026 and a net income margin of 13.22%, though valuation multiples like a P/E of 40.28 appear elevated. Positive media coverage highlights the company's strong brand and consistent performance.
The outlook remains positive given earnings beats and brand strength, but high valuation and margin pressure from input costs pose risks. Analyst consensus is mostly neutral with 71% hold ratings, suggesting cautious optimism. The stock offers stability but may face headwinds if growth slows or costs rise further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
